These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 27884751)

  • 1. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
    Osborne AL; Solowij N; Weston-Green K
    Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.
    Ortiz R; Rueda S; Di Ciano P
    Exp Clin Psychopharmacol; 2023 Oct; 31(5):978-988. PubMed ID: 37126037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
    Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
    Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model.
    Osborne AL; Solowij N; Babic I; Huang XF; Weston-Green K
    Neuropsychopharmacology; 2017 Jun; 42(7):1447-1457. PubMed ID: 28230072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the Acute and Chronic Administration of Cannabidiol on Cognition in Humans and Animals: A Systematic Review.
    Bomfim AJL; Zuze SMF; Fabrício DM; Pessoa RMP; Crippa JAS; Chagas MHN
    Cannabis Cannabinoid Res; 2023 Dec; 8(6):955-973. PubMed ID: 37792394
    [No Abstract]   [Full Text] [Related]  

  • 8. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
    Arnold JC; Boucher AA; Karl T
    Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.
    Colizzi M; Bhattacharyya S
    Curr Addict Rep; 2017; 4(2):62-74. PubMed ID: 28580227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments.
    Renard J; Norris C; Rushlow W; Laviolette SR
    Neurosci Biobehav Rev; 2017 Apr; 75():157-165. PubMed ID: 28185872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ(9) tetrahydrocannabinol.
    Wright MJ; Vandewater SA; Taffe MA
    Br J Pharmacol; 2013 Dec; 170(7):1365-73. PubMed ID: 23550724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Δ
    Silveira MM; Adams WK; Morena M; Hill MN; Winstanley CA
    J Psychiatry Neurosci; 2017 Mar; 42(2):131-138. PubMed ID: 28245177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol in medical marijuana: Research vistas and potential opportunities.
    Rong C; Lee Y; Carmona NE; Cha DS; Ragguett RM; Rosenblat JD; Mansur RB; Ho RC; McIntyre RS
    Pharmacol Res; 2017 Jul; 121():213-218. PubMed ID: 28501518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
    Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
    Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendation to reconsider examining cannabis subtypes together due to opposing effects on brain, cognition and behavior.
    Rømer Thomsen K; Callesen MB; Feldstein Ewing SW
    Neurosci Biobehav Rev; 2017 Sep; 80():156-158. PubMed ID: 28579491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol as an antipsychotic drug.
    Fabris D; Lisboa JR; Guimarães FS; Gomes FV
    Int Rev Neurobiol; 2024; 177():295-317. PubMed ID: 39029989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.